Celgene Corporation  

(Public, NASDAQ:CELG)   Watch this stock  
Find more results for CELG
123.97
-1.23 (-0.98%)
After Hours: 124.15 +0.18 (0.15%)
Apr 27, 7:18PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 122.12 - 124.98
52 week 94.42 - 127.64
Open 122.48
Vol / Avg. 0.00/3.28M
Mkt cap 96.20B
P/E 49.86
Div/yield     -
EPS 2.49
Shares 777.97M
Beta 1.78
Inst. own 81%
Jun 15, 2017
Celgene Corp Annual Shareholders Meeting (Estimated) - 1:00PM EDT - Add to calendar
Apr 27, 2017
Q1 2017 Celgene Corp Earnings Release
Apr 27, 2017
Q1 2017 Celgene Corp Earnings Call - Webcast
Mar 15, 2017
Celgene Corp at Barclays Global Healthcare Conference - Webcast
Mar 8, 2017
Celgene Corp at Cowen Health Care Conference - Webcast
Feb 15, 2017
Celgene Corp at Leerink Partners Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 14.39% 17.80%
Operating margin 21.08% 25.02%
EBITD margin - 33.76%
Return on average assets 6.27% 7.26%
Return on average equity 28.09% 31.94%
Employees 7,132 -
CDP Score - B

Address

86 Morris Ave
SUMMIT, NJ 07901-3915
United States - Map
+1-908-6739000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Officers and directors

Robert J. Hugin Executive Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Scott A. Smith President, Chief Operating Officer
Age: 54
Bio & Compensation  - Reuters
Mark J. Alles Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Peter N. Kellogg Chief Financial Officer, Executive Vice President
Age: 60
Bio & Compensation  - Reuters
Terrie Curran President, Global Inflammation & Immunology Franchise
Age: 48
Bio & Compensation  - Reuters
Thomas O. Daniel M.D. Chairman - Celgene Research
Age: 63
Bio & Compensation  - Reuters
Rupert Vessey President - Research and Early Development
Age: 52
Bio & Compensation  - Reuters
Gerald F. Masoudi Executive Vice President, General Counsel and Corporate Secretary
Age: 48
Bio & Compensation  - Reuters
Michael D. Casey Lead Independent Director
Age: 70
Bio & Compensation  - Reuters
Michael W. Bonney Director
Age: 57
Bio & Compensation  - Reuters